Amneal Pharmaceuticals (NASDAQ:AMRX) Sets New 1-Year High – Here’s What Happened

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) shares hit a new 52-week high during trading on Monday . The company traded as high as $19.74 and last traded at $20.0580, with a volume of 408257 shares trading hands. The stock had previously closed at $18.71.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on AMRX. Weiss Ratings upgraded shares of Amneal Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Wednesday, August 26th. Barclays boosted their price target on shares of Amneal Pharmaceuticals from $16.00 to $20.00 and gave the company an “overweight” rating in a report on Thursday. Zacks Research downgraded shares of Amneal Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Monday, September 7th. Leerink Partners assumed coverage on Amneal Pharmaceuticals in a report on Wednesday, September 9th. They set an “outperform” rating and a $23.00 price objective for the company. Finally, The Goldman Sachs Group reissued a “buy” rating and set a $21.00 price objective on shares of Amneal Pharmaceuticals in a research report on Friday, July 31st. Eight investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $20.14.

Amneal Pharmaceuticals Stock Up 8.2%

The stock has a market cap of $6.47 billion, a price-to-earnings ratio of 41.49 and a beta of 1.24. The business has a fifty day moving average of $17.84 and a 200 day moving average of $15.17. The company has a debt-to-equity ratio of 77.65, a current ratio of 2.20 and a quick ratio of 1.44.

Amneal Pharmaceuticals (NASDAQ:AMRX) last posted its earnings results on Thursday, July 30th. The company reported $0.30 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.24 by $0.06. The firm had revenue of $796.20 million during the quarter. Amneal Pharmaceuticals had a net margin of 5.05% and a negative return on equity of 584.46%. Amneal Pharmaceuticals has set its FY 2026 guidance at 0.960-1.060 EPS. On average, equities analysts predict that Amneal Pharmaceuticals, Inc. will post 0.94 earnings per share for the current year.

Insider Activity at Amneal Pharmaceuticals

In related news, EVP Nikita Shah sold 146,403 shares of Amneal Pharmaceuticals stock in a transaction on Wednesday, August 12th. The shares were sold at an average price of $17.51, for a total value of $2,563,516.53. Following the completion of the sale, the executive vice president owned 253,390 shares of the company’s stock, valued at approximately $4,436,858.90. The trade was a 36.62% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director John Kiely sold 50,000 shares of the company’s stock in a transaction on Thursday, August 13th. The stock was sold at an average price of $17.64, for a total transaction of $882,000.00. Following the completion of the sale, the director owned 210,252 shares of the company’s stock, valued at $3,708,845.28. This represents a 19.21% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 413,016 shares of company stock valued at $7,216,567. Insiders own 17.30% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. Dimensional Fund Advisors LP raised its stake in shares of Amneal Pharmaceuticals by 1.5% in the 1st quarter. Dimensional Fund Advisors LP now owns 5,690,586 shares of the company’s stock valued at $70,723,000 after acquiring an additional 81,546 shares in the last quarter. Allspring Global Investments Holdings LLC boosted its position in Amneal Pharmaceuticals by 72.2% during the first quarter. Allspring Global Investments Holdings LLC now owns 2,549,572 shares of the company’s stock worth $32,405,000 after purchasing an additional 1,069,400 shares during the period. Bank of New York Mellon Corp acquired a new position in Amneal Pharmaceuticals during the second quarter valued at approximately $17,573,000. Penn Capital Management Company LLC acquired a new position in Amneal Pharmaceuticals during the fourth quarter valued at approximately $12,655,000. Finally, Principal Financial Group Inc. raised its position in shares of Amneal Pharmaceuticals by 527.9% in the first quarter. Principal Financial Group Inc. now owns 972,529 shares of the company’s stock valued at $12,089,000 after purchasing an additional 817,652 shares during the period. Institutional investors and hedge funds own 31.82% of the company’s stock.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc is a specialty pharmaceutical company that develops, manufactures and commercializes a broad portfolio of generic and specialty medicines. Its products include dosage forms such as tablets, capsules, injectables, ophthalmic products and inhalation therapies, with a focus on complex generics and other products that can be more difficult to develop or manufacture.

The company also markets branded specialty pharmaceuticals in areas including central nervous system disorders, endocrinology, metabolic disease and other therapeutic categories.